Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
330 studies found for:    "Sezary syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Sezary syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Terminated Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Conditions: Sezary Syndrome;   Pruritus
Interventions: Drug: Aprepitant;   Drug: Placebo
2 Terminated Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: HuMax-CD4 (zanolimumab)
3 Completed Immunization Against Tumor Cells in Sezary Syndrome
Conditions: Cutaneous T-cell Lymphoma;   Sezary Syndrome
Intervention: Biological: Autologous Dendritic Cell Vaccine
4 Recruiting Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Campath-1H
5 Unknown  Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome
Conditions: Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: alemtuzumab
6 Not yet recruiting TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome
Conditions: Mycosis Fungoides;   Sézary Syndrome
Interventions: Radiation: TSEB Therapy;   Drug: Brentuximab vedotin
7 Recruiting Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Conditions: Mycosis Fungoides;   Sezary Syndrome;   Lymphoma, T-Cell, Cutaneous
Interventions: Drug: resminostat;   Drug: Placebo
8 Recruiting VircapSeq Virus Detection in Sézary Syndrome
Conditions: Lymphoma, T-Cell, Cutaneous;   Sézary Syndrome
Intervention:
9 Active, not recruiting Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome
Conditions: Recurrent Mycosis Fungoides and Sezary Syndrome;   Stage IB Mycosis Fungoides and Sezary Syndrome;   Stage IIA Mycosis Fungoides and Sezary Syndrome;   Stage IIB Mycosis Fungoides and Sezary Syndrome;   Stage IIIA Mycosis Fungoides and Sezary Syndrome;   Stage IIIB Mycosis Fungoides and Sezary Syndrome;   Stage IVA Mycosis Fungoides and Sezary Syndrome;   Stage IVB Mycosis Fungoides and Sezary Syndrome
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
10 Terminated Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Condition: Lymphoma
Intervention: Drug: temozolomide
11 Completed Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Condition: Lymphoma
Intervention: Drug: tretinoin
12 Terminated Interleukin-2 in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Condition: Lymphoma
Intervention: Biological: aldesleukin
13 Active, not recruiting Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
Condition: Lymphoma
Intervention: Biological: alemtuzumab
14 Not yet recruiting ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Conditions: Mycosis Fungoides;   Non-Hodgkin's Lymphoma
Intervention:
15 Completed Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma
Conditions: Mycosis Fungicides;   Sezary Syndrome;   Dermatitis;   Dermatitis, Exfoliative
Intervention: Other: Detection of KIR receptor by RT PCR
16 Active, not recruiting Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Condition: Lymphoma
Intervention: Drug: lenalidomide
17 Completed Effect of Denileukin Diftitox on Immune System in CTCL Patients
Conditions: Cutaneous T-cell Lymphoma;   Sezary Syndrome;   Mycosis Fungoides
Intervention:
18 Active, not recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Conditions: Lymphoma, Non-Hodgkin;   Cutaneous Lymphoma;   Cutaneous T Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Brentuximab vedotin
19 Terminated Gemcitabine and Pemetrexed Disodium in Treating Patients With Advanced Mycosis Fungoides or Sézary Syndrome
Condition: Lymphoma
Interventions: Drug: Gemcitabine;   Drug: Pemetrexed
20 Completed In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL)
Conditions: Cutaneous T-cell Lymphoma;   Sezary Syndrome;   Mycosis Fungoides
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.